Middle East & Africa Glioma Treatment Market Forecast to 2030
Middle East & Africa Glioma Treatment Market Forecast to 2030 – Regional Analysis – by Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), and End User (Hospital & Clinics and Ambulatory Surgical Center)
$2,485 – $3,885
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Increasing Drug Approval for Glioma Treatment Fuels Middle East & Africa Glioma Treatment Market
In recent years, there has been a notable increase in the approval of drugs to treat gliomas, marking a significant step forward in addressing the challenges posed by these severe brain tumors. Growing awareness of the urgent need for effective therapeutic options and the dedicated efforts of researchers and pharmaceutical companies to develop innovative treatments are leading to the development and approval of these drugs. Targeted therapies have been a key focus of researchers working on glioma treatment, wherein drugs are designed to specifically target molecular alterations or signaling pathways crucial for glioma cells’ survival and growth. These therapies aim to disrupt the tumor’s ability to expand while sparing healthy brain tissue. In June 2022, the FDA approved two targeted therapy drugs to be taken in combination—Dabrafenib and Trametinib. These drugs attack the cancerous cells that have undergone the BRAF mutation. The drugs stop the mutated cells from sending growth signals to other cells.
Drug manufacturers have been emphasizing the use of cutting-edge technologies. Kiyatec’s ex vivo 3D cell culture technology for high-grade glioma received new clinical data at ASCO 2022. Thus, an increasing number of drug approvals for treating glioma would result in notable growth trends in the glioma treatment market in the near future.
Middle East & Africa Glioma Treatment Market Overview
The UAE, Saudi Arabia, and South Africa are important countries in the Middle East & Africa. The UAE accounts for the largest share of the glioma treatment market in this region. The market is driven by extensive medical studies undertaken by several research institutes, and the availability of infrastructure and facilities for providing brain tumor treatment in the UAE and Saudi Arabia. The UAE serves vital growth opportunities for the healthcare diagnostics business. It has a leading healthcare sector among all Arab countries, which continuously seeks ways to embrace sustainable operations through economic development. Further, government initiatives to encourage research and development, and increase in healthcare expenditure benefit the glioma treatment market in the UAE. Many international glioma treatment market players are entering the South African marketplace to expand their businesses and reach a larger customer base directly. Other major countries contributing to the glioma treatment market growth in the Middle East & Africa, which have been focusing on improving their healthcare infrastructure by allowing new market players to enter into their healthcare markets.
Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Million)
Middle East & Africa Glioma Treatment Market Segmentation
The Middle East & Africa glioma treatment market is segmented into disease, treatment type, grade, end user, and country.
Based on disease, the Middle East & Africa glioma treatment market is segmented into astrocytoma, oligoastrocytoma, and oligodendroglioma. The astrocytoma segment held the largest share of the Middle East & Africa glioma treatment market in 2022.
Based on treatment type, the Middle East & Africa glioma treatment market is segmented into surgery, chemotherapy, radiation therapy, and others. The surgery segment held the largest share of the Middle East & Africa glioma treatment market in 2022.
Based on grade, the Middle East & Africa glioma treatment market is segmented into low grade and high grade. The high grade segment held a larger share of the Middle East & Africa glioma treatment market in 2022.
Based on end user, the Middle East & Africa glioma treatment market is segmented into hospital & clinics and ambulatory surgical center. The hospital & clinics segment held a larger share of the Middle East & Africa glioma treatment market in 2022.
Based on country, the Middle East & Africa glioma treatment market is segmented int o Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. The Rest of Middle East & Africa dominated the Middle East & Africa glioma treatment market in 2022.
Amgen Inc, Amneal Pharmaceuticals Inc, Biocon Ltd, F. Hoffmann-La Roche Ltd, Karyopharm Therapeutics Inc, Merck & Co Inc, Pfizer Inc, Sun Pharmaceutical Industries Ltd, and Teva Pharmaceutical Industries Ltd are some of the leading companies operating in the Middle East & Africa glioma treatment market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Geographical coverage: | |
| Year of Publication: |
According to the research team’ research, the Middle East & Africa glioma treatment market was valued at US$ 127.60 million in 2022 and is expected to reach US$ 243.45 million by 2030, registering a CAGR of 8.4% from 2022 to 2030. Increase in prevalence of high-grade glioma and increasing opportunities in emerging economies are among the critical factors attributed to the Middle East & Africa glioma treatment market expansion.
High-grade gliomas include aggressive brain tumors such as glioblastomas, anaplastic astrocytomas, and oligodendrogliomas. These tumors are characterized by their rapid growth, infiltrative behavior, and resistance to conventional treatment methods. High-grade gliomas are multifaceted tumors that are not yet fully understood, which is a major reason for their increasing incidence. Moreover, aging populations, environmental exposure, genetic predispositions, and improved diagnostic capabilities are other notable factors that result in a large number of cases. Gliomas, particularly glioblastomas, are known for their devastating impact on patients’ lives due to their location within the brain and ability to disrupt critical neurological functions.
The most frequent and dangerous type of brain tumor is glioblastoma. Globally, more than 250,000 new cases of primary malignant brain tumors are detected each year, with gliomas accounting for 77% of these occurrences. It still remains a rare disease, accounting for over 50% of primary malignant brain tumors.
On the contrary, the high cost of diagnosis hampers the Middle East & Africa glioma treatment market.
Based on disease, the Middle East & Africa glioma treatment market is segmented into astrocytoma, oligoastrocytoma, and oligodendroglioma. The astrocytoma segment held 71.2% share of Middle East & Africa glioma treatment market in 2022, amassing US$ 90.90 million. It is projected to garner US$ 178.29 million by 2030 to expand at 8.8% CAGR during 2022-2030.
Based on treatment type, the Middle East & Africa glioma treatment market is segmented into surgery, chemotherapy, radiation therapy, and others. The surgery segment held 48.5% share of Middle East & Africa glioma treatment market in 2022, amassing US$ 61.92 million. It is projected to garner US$ 123.49 million by 2030 to expand at 9.0% CAGR during 2022-2030.
Based on grade, the Middle East & Africa glioma treatment market is segmented into low grade and high grade. The high grade segment held 79.0% share of Middle East & Africa glioma treatment market in 2022, amassing US$ 100.79 million. It is projected to garner US$ 196.06 million by 2030 to expand at 8.7% CAGR during 2022-2030.
Based on end user, the Middle East & Africa glioma treatment market is segmented into hospital & clinics and ambulatory surgical center. The hospital & clinics segment held 79.8% share of Middle East & Africa glioma treatment market in 2022, amassing US$ 101.81 million. It is projected to garner US$ 195.42 million by 2030 to expand at 8.5% CAGR during 2022-2030.
Based on country, the Middle East & Africa glioma treatment market has been categorized into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Our regional analysis states that the Rest of Middle East & Africa captured 32.9% share of Middle East & Africa glioma treatment market in 2022. It was assessed at US$ 41.93 million in 2022 and is likely to hit US$ 76.54 million by 2030, exhibiting a CAGR of 7.8% during 2022-2030.
Key players operating in the Middle East & Africa glioma treatment market are Amgen Inc, Amneal Pharmaceuticals Inc, Biocon Ltd, F. Hoffmann-La Roche Ltd, Karyopharm Therapeutics Inc, Merck & Co Inc, Pfizer Inc, Sun Pharmaceutical Industries Ltd, and Teva Pharmaceutical Industries Ltd, among others.
o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa Glioma Treatment market.
o Highlights key in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa Glioma Treatment market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
TABLE OF CONTENTS
1. Introduction
1.1 The Research Team Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Middle East & Africa Glioma Treatment Market – Key Industry Dynamics
4.1 Market Drivers
4.1.1 Government Funding for Glioma Treatment
4.1.2 Increase in Prevalence of High-Grade Glioma
4.2 Key Market Restraints
4.2.1 High Cost of Diagnosis
4.3 Key Market Opportunities
4.3.1 Advancements in Healthcare Sector in Emerging Economies
4.4 Future Trends
4.4.1 Surge in Drug Approvals for Glioma Treatment
4.5 Impact Analysis:
5. Middle East & Africa Glioma Treatment Market – Middle East & Africa Market Analysis
5.1 Middle East & Africa Glioma Treatment Market Revenue (US$ Mn), 2022 – 2030
6. Middle East & Africa Glioma Treatment Market – Revenue and Forecast to 2030 – by Disease
6.1 Overview
6.2 Middle East & Africa Glioma Treatment Market Revenue Share, by Disease 2022 & 2030 (%)
6.3 Astrocytoma
6.3.1 Overview
6.3.2 Astrocytoma: Middle East & Africa Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Oligoastrocytoma
6.4.1 Overview
6.4.2 Oligoastrocytoma: Middle East & Africa Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
6.5 Oligodendroglioma
6.5.1 Overview
6.5.2 Oligodendroglioma: Middle East & Africa Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
7. Middle East & Africa Glioma Treatment Market – Revenue and Forecast to 2030 – by Treatment Type
7.1 Overview
7.2 Middle East & Africa Glioma Treatment Market Revenue Share, by Treatment Type 2022 & 2030 (%)
7.3 Surgery
7.3.1 Overview
7.3.2 Surgery: Middle East & Africa Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Chemotherapy
7.4.1 Overview
7.4.2 Chemotherapy: Middle East & Africa Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Radiation Therapy
7.5.1 Overview
7.5.2 Radiation Therapy: Middle East & Africa Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: Middle East & Africa Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
8. Middle East & Africa Glioma Treatment Market – Revenue and Forecast to 2030 – by Grade
8.1 Overview
8.2 Middle East & Africa Glioma Treatment Market Revenue Share, by Grade 2022 & 2030 (%)
8.3 Low Grade
8.3.1 Overview
8.3.2 Low Grade: Middle East & Africa Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
8.3.2.1 Grade I: Middle East & Africa Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
8.3.2.2 Grade II: Middle East & Africa Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
8.4 High Grade
8.4.1 Overview
8.4.2 High Grade: Middle East & Africa Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
8.4.2.1 Grade III: Middle East & Africa Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
8.4.2.2 Grade IV: Middle East & Africa Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
9. Middle East & Africa Glioma Treatment Market – Revenue and Forecast to 2030 – by End User
9.1 Overview
9.2 Middle East & Africa Glioma Treatment Market Revenue Share, by End User 2022 & 2030 (%)
9.3 Hospital & Clinics
9.3.1 Overview
9.3.2 Hospital & Clinics: Middle East & Africa Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Ambulatory Surgical Centers
9.4.1 Overview
9.4.2 Ambulatory Surgical Centers: Middle East & Africa Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
10. Glioma Treatment Market – Middle East & Africa Analysis
10.1.1 Overview
10.1.2 Middle East & Africa Glioma Treatment Market, by Country
10.1.2.1 Saudi Arabia
10.1.2.1.1 Saudi Arabia: Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
10.1.2.1.2 Saudi Arabia: Middle East & Africa Glioma Treatment Market, by Disease
10.1.2.1.3 Saudi Arabia: Middle East & Africa Glioma Treatment Market, by Treatment Type
10.1.2.1.4 Saudi Arabia: Middle East & Africa Glioma Treatment Market, by Grade
10.1.2.1.4.1 Saudi Arabia: Middle East & Africa Glioma Treatment Market, by Low Grade
10.1.2.1.4.2 Saudi Arabia: Middle East & Africa Glioma Treatment Market, by High Grade
10.1.2.1.5 Saudi Arabia: Middle East & Africa Glioma Treatment Market, by End User
10.1.2.2 South Africa
10.1.2.2.1 South Africa: Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
10.1.2.2.2 South Africa: Middle East & Africa Glioma Treatment Market, by Disease
10.1.2.2.3 South Africa: Middle East & Africa Glioma Treatment Market, by Treatment Type
10.1.2.2.4 South Africa: Middle East & Africa Glioma Treatment Market, by Grade
10.1.2.2.4.1 South Africa: Middle East & Africa Glioma Treatment Market, by Low Grade
10.1.2.2.4.2 South Africa: Middle East & Africa Glioma Treatment Market, by High Grade
10.1.2.2.5 South Africa: Middle East & Africa Glioma Treatment Market, by End User
10.1.2.3 UAE
10.1.2.3.1 UAE: Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
10.1.2.3.2 UAE: Middle East & Africa Glioma Treatment Market, by Disease
10.1.2.3.3 UAE: Middle East & Africa Glioma Treatment Market, by Treatment Type
10.1.2.3.4 UAE: Middle East & Africa Glioma Treatment Market, by Grade
10.1.2.3.4.1 UAE: Middle East & Africa Glioma Treatment Market, by Low Grade
10.1.2.3.4.2 UAE: Middle East & Africa Glioma Treatment Market, by High Grade
10.1.2.3.5 UAE: Middle East & Africa Glioma Treatment Market, by End User
10.1.2.4 Rest of Middle East & Africa
10.1.2.4.1 Rest of Middle East & Africa: Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
10.1.2.4.2 Rest of Middle East & Africa: Middle East & Africa Glioma Treatment Market, by Disease
10.1.2.4.3 Rest of Middle East & Africa: Middle East & Africa Glioma Treatment Market, by Treatment Type
10.1.2.4.4 Rest of Middle East & Africa: Middle East & Africa Glioma Treatment Market, by Grade
10.1.2.4.4.1 Rest of Middle East & Africa: Middle East & Africa Glioma Treatment Market, by Low Grade
10.1.2.4.4.2 Rest of Middle East & Africa: Middle East & Africa Glioma Treatment Market, by High Grade
10.1.2.4.5 Rest of Middle East & Africa: Middle East & Africa Glioma Treatment Market, by End User
11. Glioma Treatment Market Industry Landscape
11.1 Overview
11.2 Growth Strategies Done by the Companies in the Market, (%)
11.3 Organic Developments
11.3.1 Overview
11.4 Inorganic Developments
11.4.1 Overview
12. Company Profiles
12.1 F. Hoffmann-La Roche Ltd
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Merck & Co Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Sun Pharmaceutical Industries Ltd
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Amgen Inc
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Teva Pharmaceutical Industries Ltd
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Pfizer Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Amneal Pharmaceuticals Inc
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Karyopharm Therapeutics Inc
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Biocon Ltd
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
13. Appendix
13.1 About Us
13.2 Glossary of Terms
LIST OF TABLES
Table 1. Middle East & Africa Glioma Treatment Market Segmentation
Table 2. Saudi Arabia: Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – Disease
Table 3. Saudi Arabia: Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – Treatment Type
Table 4. Saudi Arabia: Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
Table 5. Saudi Arabia: Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – Low Grade
Table 6. Saudi Arabia: Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
Table 7. Saudi Arabia: Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – End User
Table 8. South Africa: Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – Disease
Table 9. South Africa: Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – Treatment Type
Table 10. South Africa: Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
Table 11. South Africa: Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
Table 12. South Africa: Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – High Grade
Table 13. South Africa: Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – End User
Table 14. UAE: Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – Disease
Table 15. UAE: Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – Treatment Type
Table 16. UAE: Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
Table 17. UAE: Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
Table 18. UAE: Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
Table 19. UAE: Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – End User
Table 20. Rest of Middle East & Africa: Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – Disease
Table 21. Rest of Middle East & Africa: Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – Treatment Type
Table 22. Rest of Middle East & Africa: Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
Table 23. Rest of Middle East & Africa: Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
Table 24. Rest of Middle East & Africa: Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
Table 25. Rest of Middle East & Africa: Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – End User
Table 26. Organic Developments Done By Companies
Table 27. Inorganic Developments Done By Companies
Table 28. Glossary of Terms, glioma treatment market
LIST OF FIGURES
Figure 1. Middle East & Africa Glioma Treatment Market Segmentation, By Country
Figure 2. Middle East & Africa Glioma Treatment Market – Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Middle East & Africa Glioma Treatment Market Revenue (US$ Mn), 2022 – 2030
Figure 5. Middle East & Africa Glioma Treatment Market Revenue Share, by Disease 2022 & 2030 (%)
Figure 6. Astrocytoma: Middle East & Africa Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Oligoastrocytoma: Middle East & Africa Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Oligodendroglioma: Middle East & Africa Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Middle East & Africa Glioma Treatment Market Revenue Share, by Treatment Type 2022 & 2030 (%)
Figure 10. Surgery: Middle East & Africa Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Chemotherapy: Middle East & Africa Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Radiation Therapy: Middle East & Africa Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: Middle East & Africa Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Middle East & Africa Glioma Treatment Market Revenue Share, by Grade 2022 & 2030 (%)
Figure 15. Low Grade: Middle East & Africa Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Grade I: Middle East & Africa Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Grade II: Middle East & Africa Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. High Grade: Middle East & Africa Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Grade III: Middle East & Africa Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. Grade IV: Middle East & Africa Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 21. Middle East & Africa Glioma Treatment Market Revenue Share, by End User 2022 & 2030 (%)
Figure 22. Hospital & Clinics: Middle East & Africa Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 23. Ambulatory Surgical Centers: Middle East & Africa Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 24. Middle East & Africa Glioma Treatment Market, By Country, 2022 ($Mn)
Figure 25. Middle East & Africa Glioma Treatment Market, By Key Countries, 2022 And 2030 (%)
Figure 26. Saudi Arabia: Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 27. South Africa: Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 28. UAE: Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 29. Rest of Middle East & Africa: Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 30. Growth Strategies Done by the Companies in the Market, (%)
The List of Companies – Middle East & Africa Glioma Treatment Market
1. Amgen Inc
2. Amneal Pharmaceuticals Inc
3. Biocon Ltd
4. F. Hoffmann-La Roche Ltd
5. Karyopharm Therapeutics Inc
6. Merck & Co Inc
7. Pfizer Inc
8. Sun Pharmaceutical Industries Ltd
9. Teva Pharmaceutical Industries Ltd
You must be logged in to post a review.
Reviews
There are no reviews yet.